Detection of mecA Gene in Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated from Diabetic Ulcer Swab Samples
Abstract
Diabetic ulcers represent a serious complication of diabetes mellitus, often becoming chronic wounds prone to infection due to impaired immunity, poor vascularization, and persistent hyperglycemia. Among the most frequently identified pathogens in such wounds is Staphylococcus aureus, with methicillin-resistant S. aureus (MRSA) strains posing significant therapeutic challenges due to their resistance to β-lactam antibiotics. This resistance is typically mediated by the mecA gene, which encodes penicillin-binding protein 2a (PBP2a), a protein with reduced affinity for β-lactams. This study aimed to detect the presence of the mecA gene in MRSA strains isolated from diabetic ulcer swabs and to examine the relationship between phenotypic resistance and genotypic confirmation. A total of 30 swab samples were collected from patients with diabetic ulcers at the Diabetes Wound Care Clinic in Surabaya. Bacterial identification was performed using standard microbiological techniques, and cefoxitin disk diffusion was used to screen for MRSA phenotypically. Genomic DNA from cefoxitin-resistant isolates was subjected to conventional PCR using mecA-specific primers, with electrophoresis to detect the expected 304 bp DNA fragment. Of the 30 samples, 19 (63%) were confirmed to be S. aureus, and among them, 6 isolates (31.6%) were resistant to cefoxitin. However, none of these isolates were positive for the mecA gene by PCR, although the positive control showed the expected band. This discrepancy suggests the possibility of other resistance mechanisms beyond mecA, highlighting the importance of molecular methods in confirming MRSA. These findings reinforce the need for integrated phenotypic and genotypic diagnostics to ensure accurate detection and appropriate treatment of MRSA infections
Full text article
References
[1] B. A. Lipsky et al., “IWGDF guideline on the diagnosis and treatment of foot infection in persons with diabetes,” Diabetes Metab. Res. Rev., vol. 36, no. S1, 2020.
[2] J. Aragón-Sánchez, “Diabetic foot infections,” World J. Diabetes, vol. 11, no. 6, 2020.
[3] Y. Zhang et al., “Biofilm-associated antibiotic resistance in Staphylococcus aureus,” Front. Microbiol., vol. 14, 2023.
[4] WHO, Global priority list of antibiotic-resistant bacteria, Geneva, 2020.
[5] CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed., 2022.
[6] S. Lakhundi and K. Zhang, “Methicillin-resistant Staphylococcus aureus,” Clin. Microbiol. Rev., vol. 31, no. 4, 2018.
[7] S. Rostami et al., “Comparison of mecA PCR and cefoxitin disk diffusion,” Afr. J. Microbiol. Res., vol. 7, 2021.
[8] K. Becker et al., “Rapid molecular detection of MRSA,” J. Clin. Microbiol., vol. 58, 2020.
[9] H. Zhu et al., “PCR: past, present, and future,” Biotechniques, vol. 69, 2020.
[10] W. Chen et al., “CRISPR-based detection of MRSA,” Front. Microbiol., vol. 15, 2024.
[11] P. Santos et al., “MALDI-TOF MS biomarkers for MRSA,” Clin. Microbiol. Infect., vol. 31, 2025.
[12] A. C. Fluit et al., “Antimicrobial resistance in developing countries,” Lancet Infect. Dis., vol. 21, 2021.
[13] C. Lozano et al., “Clinical relevance of mecC-positive MRSA,” Microorganisms, vol. 8, 2020.
[14] M. M. Hryniewicz and K. Garbacz, “BORSA: an underestimated problem,” J. Med. Microbiol., vol. 69, 2020.
[15] V. Panchal et al., “High-level β-lactam resistance mechanisms,” PLoS Pathog., vol. 16, 2020.
[16] F. M. Lowy, “Antimicrobial resistance in Staphylococcus aureus,” J. Clin. Invest., vol. 131, 2021.
[17] D. Erikawati et al., “MRSA prevalence in Indonesia,” Acta Med. Indones., vol. 52, 2020.
[18] E. Warganegara et al., “Phenotypic MRSA detection limitations,” J. Kedokt. Brawijaya, vol. 34, 2022.
[19] M. Ayu et al., “Detection of mecA gene using PCR,” J. Biol. Tropis, vol. 24, 2024.
[20] S. Otto, “MRSA virulence and spread,” Cell. Microbiol., vol. 24, 2022.
[21] L. A. Lavery et al., “Risk factors for MRSA infection in diabetic foot ulcers,” Int. Wound J., vol. 17, no. 6, 2020.
[22] J. Aragón-Sánchez, “Management of diabetic foot infections,” World J. Diabetes, vol. 11, no. 6, 2020.
[23] K. Becker et al., “Laboratory diagnosis of Staphylococcus aureus,” Clin. Microbiol. Rev., vol. 33, no. 3, 2020.
[24] CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed., 2022.
[25] H. Zhu et al., “PCR: past, present, and future,” Biotechniques, vol. 69, no. 4, 2020.
[26] M. Ayu et al., “Detection of the mecA gene in MRSA using PCR,” J. Biol. Tropis, vol. 24, no. 1, 2024.
[27] S. Rostami et al., “Comparison of phenotypic and genotypic MRSA detection,” Afr. J. Microbiol. Res., vol. 15, 2021.
[28] W. Chen et al., “Molecular approaches for MRSA detection,” Front. Microbiol., vol. 15, 2024
[29] E. Erikawati et al., “MRSA surveillance in Indonesia,” Acta Med. Indones., vol. 52, no. 4, 2020.
[30] Y. Zhang et al., “Biofilm-associated antibiotic resistance in Staphylococcus aureus,” Front. Microbiol., vol. 14, 2023.
[31] CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed., 2022.
[32] M. M. Hryniewicz and K. Garbacz, “Borderline oxacillin-resistant Staphylococcus aureus (BORSA),” J. Med. Microbiol., vol. 69, 2020.
[33] L. A. Lavery et al., “Microbiology of diabetic foot infections,” Int. Wound J., vol. 17, no. 6, 2020.
[34] J. Aragón-Sánchez, “Clinical significance of MRSA in diabetic foot infections,” World J. Diabetes, vol. 11, 2020.
[35] S. Rostami et al., “Comparison of phenotypic and genotypic MRSA detection,” Afr. J. Microbiol. Res., vol. 15, 2021.
[36] K. Becker et al., “Emerging MRSA detection strategies,” J. Clin. Microbiol., vol. 58, 2020.
[37] C. Lozano et al., “Clinical relevance of mecC-positive MRSA,” Microorganisms, vol. 8, 2020.
[38] W. Chen et al., “Molecular approaches for MRSA characterization,” Front. Microbiol., vol. 15, 2024.
[39] F. M. Lowy, “Antimicrobial resistance in Staphylococcus aureus,” J. Clin. Invest., vol. 131, 2021.
[40] WHO, Global Antimicrobial Resistance Surveillance System (GLASS) Report, 2023.
Authors
Copyright (c) 2025 Aliyya Noor Izzati, Suliati, Lully Hanni Endarini, Syamsul Arifin
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlikel 4.0 International (CC BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).